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The high-yielding synthesis of enantiomerically pure epicatechin gallate analogues where the A and/or
B-ring hydroxylation is reduced or altered has been achieved by optimising routes to the catechin ste-
reochemistry. The B-ring analogues were synthesised by using an electrophilic ring closure onto an
enantiomerically enriched epoxide as a key step. The A and B-ring hydroxyl-deleted analogues were
synthesised through a Mitsunobu cyclisation. For the B-ring analogues, the anti- (catechin) stereo-
chemistry was converted to the syn- (epicatechin) stereochemistry by a known oxidation/reduction
protocol. Absolute stereochemistry was derived from either a Sharpless epoxidation or asymmetric
dihydroxylation.
 2014 The Authors. Published by Elsevier Ltd. All rights reserved.1. Introduction
Galloyl catechins, such as ()-epicatechin gallate (ECg), ()-epi-
gallocatechin gallate (EGCg) and ()-catechin gallate (Cg) are natural
polyphenols, which constitute around 10% of the dry leaf weight of
the green tea plant Camellia sinensis.1 They have negligible antibac-
terial activity themselves, but show the capacity, at relatively low
concentrations, to disrupt the b-lactam resistance machinery of
methicillin-resistant strains of Staphylococcus aureus (MRSA), in-
ducing complete but reversible susceptibility to a wide range of b-
lactamdrugs.2e4 There is strongevidence that this effect isdependent
on the intercalation of the bioactive polyphenols into the bacterial
cytoplasmic membrane (CM): the most potent modiﬁer, ECg (Fig. 1),
inserts into the staphylococcal bilayer, inducing a series of complex
changes to the phospholipid palisade and leading to reduction in the
efﬁciency of function of CM-embedded proteins, such as the
penicillin-binding proteins responsible for peptidoglycan bio-
synthesis and b-lactam resistance.5,6 ECg differs from EGCg only by
the absence of a hydroxyl function at one of themeta positions on the
B-ring (Fig.1), suggesting that reducing thedegreeofhydroxylationor
altering thepositionof hydroxyl groupson theB-ringpharmacophorer the CC BY license
-mail address: j.c.anderson@
. Published by Elsevier Ltd. All righmay increasebilayer afﬁnity,with consequent increases inbioactivity.
We therefore synthesized a number of unnatural ECg analogues dif-
fering in B-ring hydroxylation and in hydroxyl substitution of the
fused AeC-ring moiety (Fig. 1).7,8 We demonstrated that while
monohydroxylated 3-hydroxy B-ring 1 and dihydroxylated 3,5-
dihydroxy B-ring 2 ECg analogues sensitized MRSA strains to the b-
lactam antibiotic oxacillin to a comparable extent compared to the
natural product, the complete deletion of all B-ring hydroxyl groups
gave a compound 3 that displayed an enhanced capacity to reduce
oxacillin resistance in EMRSA-16 (Fig.1).8 Complete deletion of A and
B ring hydroxyl groups in either epicatechin 4 or catechin ()-5
resulted in a reduction in b-lactam resistance-modifying potential
and an increase in intrinsic anti-staphylococcal activity, with the
catechin derivative ()-5 showing an enhanced effect. We reported
that further reduction of B-ring hydroxyl substitution led to lower
synthetic yields.8 In order to investigate the capacity of natural and
synthetic galloyl catechins, as well as combinations of galloyl and
non-galloyl catechins, to interact with artiﬁcial membrane bilayers
and indicate the potential for creating therapeutic catechin combi-
nations for modulation of staphylococcal b-lactam resistance, we
requiredamore robust synthesis of thesehydroxyl deletedanalogues.
Here we report an improved synthesis of these analogues, as well as
the synthesis of thenovel enantiomerof ()-5 [(þ)-5],whichwehave
used in further studies of our own9 and we hope will be of use to
others investigating the wide range of other biological effects
exhibited by catechins in general.10ts reserved.
Fig. 1. Naturally occurring galloyl catechins and non-natural targets.
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Our previous synthesis of these compounds, which was also
developed by Chan,11 introduced the desired stereochemistry using
a Sharpless dihydroxylation followed by a four-step cyclisation
(Scheme 1).7,8 We have since found that the reproducibility of the
cyclisation to form ring C is highly dependent on the purity of the
acetyl bromide used. This must be freshly distilled and the presence
of any HBr leads to a largemixture of often inseparable compounds,
erosion of stereochemical integrity and low yields (typically less
than 10%).Scheme 1. Reagents and conditions (i) AD-mix-b. (ii) HCl, MeOH. (iii) HC(OMe)3,
PPTS cat. (iv) AcBr; K2CO3. (v) NaBH4.
Scheme 2. Reagents and conditions (i) mcpba, CH2Cl2, 4 h, 52%. (ii) 3,5-
Dibenzoxyphenol, NaH, THF, H2O, reﬂux, 14 h, 61%. (iii) Et3N, TMSCl, EtOAc, 20 C,
25 min, then MsCl, Et3N, 20 min followed by 2 M HCl (used crude in next step). (iv)
NaOH, Bu4NCl, H2O, THF, 14 h, 73% over two steps.As 100 mg quantities of each compound were required for
membrane bilayer studies we set about to develop a more reliable
and reproducible synthesis of the desired analogues. Natural EGCg
can be readily synthesised using a Mitsunobu cyclisation to form
ring C to give the catechin followed by an oxidation and reduction
to give the epicatechin.12 We investigated a range of conditions for
the Mitsunobu cyclisations of the B-ring diminished hydroxyl
compounds (1, 2, 3) along the same route, but found that in the
absence of the para-hydroxy group on the B ring no desired product
formation occurred. Since our publication of the synthesis of 2 and
3 in 20057 and the synthesis of 1 and 4 in 20118 a number of
publications have appeared on the synthesis of various other epi-
catechin analogues (with orwithout the gallate ester), which do not
have a para-hydroxyl group on the B-ring. A recentmethod replaces
the capricious acetyl bromide used in our previous cyclisations
with BF3$OEt2 to good effect, although only cyclises substrates to
the anti-stereochemistry (catechin like) and in racemic form.13 We
were drawn to the more efﬁcient route of Yang et al. who reported
the synthesis of a range of catechins using a thiourea/AuCl3/AgOTf
catalysed diastereoselective annulation of aryl epoxides (Eq. 1).14
Qu et al. have reported a similar strategy for the synthesis of 3-
chromanol analogues, in this case the cyclisation of a similar ep-
oxide was performed by reﬂuxing the substrate in hexa-
ﬂuoroisopropanol (HFIP), but again only on substrates, which gave
the (anti-) catechin relative stereochemistry.15 They also had one
example of the synthesis of a catechin analogous to 3 but with
methyl ether protecting groups performed using enantiopure
epoxide.It was thought that this methodology could be applied to the
synthesis of our analogues. Use of benzyl protecting groups on the
phenolic hydroxyls would enable the synthesis of the ECg ana-
logues with free phenolic hydroxyl groups after hydrogenolysis. We
are not aware of any examples of the deprotection of methoxy
groups on either (epi)catechins or the corresponding gallate esters.
The thiourea catalyst used in Eq.1 is not commercially available and
the synthesis of this compound involves multiple steps, in addition
to the use of an expensive gold catalyst. In contrast to this the HFIP
cyclisation requires no additional catalyst and the solvent can be
recycled and reused by a simple distillation at the end of the re-
action. Although the reaction for the methoxy-substituted catechin
analogous to 3 was slow (72 hd51% conversion) we decided to
pursue this reaction in favour of the gold-catalysed cyclisation.
For the synthesis of analogue 3 we initially attempted to syn-
thesise the desired racemic epicatechin 7 with the correct syn-
relative stereochemistry directly from the diastereomeric epoxide 8
compared to Yang14 and Qu15 (Scheme 2). However all attempts at
cyclising 8 utilising HFIP failed, starting material and HFIP addition
to the epoxide was detected in the crude reaction mixture by 1H
NMR spectroscopy. The failure of 8 to cyclise under these reaction
conditions is in direct contrast to the literature example (Fig. 1).
Inspection of molecular models reveals steric crowding between
each of the aromatic rings and the methylene of the epoxide in the
reactive conformation required for ring closure. For the di-
astereoisomer in Fig. 1, the C6H5-group is orientated exo- to the
bond forming event in the same conformation.
Scheme 4. Reagents and conditions (i) PPh3, DEAD, THF, 14 h (12: 46%, 13: 64%). (ii)
BzCl, Et3N, DMAP (cat.), CH2Cl2, 15 h. (iii) Pd(OH)2/C, EtOAc/MeOH, 2.5 h (()-5: 57%),
(þ)-5: 53% over two steps).
J.C. Anderson et al. / Tetrahedron 70 (2014) 3485e3490 3487We therefore reverted to the diastereomeric epoxide 10a anal-
ogous to Qu’s compound.15 The enantiomerically pure epoxide 6a
(96% ee) was generated by Sharpless epoxidation16 of cinnamoyl
alcohol and the epoxide synthesised for this substrate in an anal-
ogous way to epoxides synthesised by Qu. Heating 10a in HFIP gave
the desired cyclised catechin 11a in 46% yield (56% b.r.s.m), al-
though long reaction times were needed (15 d). The desired epi-
catechin relative stereochemistry was attained by oxidation of the
alcohol with DesseMartin periodinane and reduction of the gen-
erated ketone with L-Selectride to give 7a in high overall yield.17
The desired gallate ester product 3 was synthesised using our
previously published procedure8 involving the DMAP-catalysed
coupling of the benzyl-protected gallate acid chloride followed by
global hydrogenolysis to remove the benzyl protecting groups. By
changing the solvent of the hydrogenation to a mixture of EtOAc
and MeOH (compared to previously using just EtOAc) and in-
creasing the reaction time to 12 h the yield of this step could be
increased from 37 to 95% (depending on analogue) to near quan-
titative conversion in all cases.
This synthesis was also successful for the mono- and di-
hydroxy-substituted B ring analogues (1 and 2). In these cases
enantiopurity was determined by the formation of the Mosher
ester of the epoxides 6b,c as no separation was seen of the ra-
cemic epoxides using chiral HPLC. In both cases the enantio-
purity was found to be >95% by 1H NMR analysis. The
enantiopurity of all the epicatechin compounds and gallate es-
ters was judged to be maintained through the synthetic se-
quence (Scheme 3) by comparison to our previously reported
speciﬁc rotations.8Scheme 3. Reagents and conditions (i) DiethyleL-tartrate, Ti(OiPr)4, t-BuOOH, sieves,
CH2Cl2, 20 C (6a: 40%, 6b: 70%, 6c: 79%). (ii) 3,5-Dibenzoxyphenol, NaH, THF, H2O,
reﬂux, 14 h (9a: 61%, 9b: 61%, 9c: 78%). (iii) 10a: Pyridine, p-tosyl chloride, rt, 2 d then
K2CO3 (67%); 10b,c: Et3N, DMAP, p-tosyl chloride, CH2Cl2, rt, o/n then K2CO3 (10b: 46%,
10c: 56%). (iv) HFIP, reﬂux 12e15 d (11a: 46%, 11b: 42%, 11c: 33%). (v) DesseMartin
periodinane, wet CH2Cl2, 0 C, o/n (a: 63%, b: 57%, c: 68%). (vi) L-Selectride, THF,
78 C, 2 h (7a: 72%, 7b: 68%, 7c: 74%).The synthesis of our last analogues 5 was more facile. The
Mitsunobu cyclisation of requisite triols has been reported by
Krohn to give ()-catechin.18 We repeated this reaction using both
the known triols8,18 synthesised using a-ADmix and b-ADmix to
give cyclised compounds 12 and 13.19 Subsequent coupling with
the benzyl-protected gallate acid chloride and hydrogenolysis gave
()-5 and the novel (þ)-5 (Scheme 4).3. Conclusion
Reducing the degree of hydroxylation or altering the position of
hydroxyl groups on the A and/or B-ring pharmacophore has a pro-
found effect on the ability of non-natural epicatechin gallate ana-
logues to modulate staphylococcal b-lactam resistance, and also on
their syntheses. The syntheses of these molecules have proven low-
yielding due to decreased activation of the aromatic rings.7,8 We
have optimised synthetic routes to prepare these compounds in
high yielding procedures, which allows for their synthesis in
quantities sufﬁcient for further studies to explore and quantify
interactions with artiﬁcial membrane bilayers and indicate the
potential for creating therapeutic catechin combinations for mod-
ulation of staphylococcal b-lactam resistance.9 The synthetic routes
to the B-ring analogues rely upon formation of the anti- (catechin)
stereochemistry, which was then converted to the syn- (epi-
catechin) stereochemistry by a known oxidation/reduction pro-
tocol.17 Absolute stereochemistry was derived from either
a Sharpless epoxidation16 or asymmetric dihydroxylation.19 The
synthetic routes will be of use to others investigating the wide
range of biological effects exhibited by catechin analogues in
general.
4. Experimental section
4.1. General
Melting points were recorded on a Stuart Scientiﬁc SMP3 ap-
paratus and are uncorrected. Optical rotations were recorded on
a PerkineElmer 343 digital polarimeter at 22 C and are reported in
deg cm2 g1. Infrared spectra were recorded on a PerkineElmer
1600 FTIR instrument as thin ﬁlms or solids. The NMR spectra were
recorded on Bruker AVANCE III 600 MHz spectrometer as a solution
in CDCl3 unless otherwise stated. Chemical shifts are reported in
parts per million relative to CHCl3 (1H: 7.27), (13C: 77.2). Coupling
constants are reported in Hertz and rounded to the nearest 0.1 Hz.
Signal assignments are as follows: br (broad), s (singlet), d (dou-
blet), t (triplet), q (quartet), m (multiplet), dd (doublet of doublets),
etc. Mass spectra were recorded using Thermo Finnigan Mat900xp
(EI/CI) and Waters LCT Premier XE (ES) instruments. HPLC analysis
was acquired on a Hewlett Packard Capillary HP4890A GC analyser.
For all non-aqueous chemistry, glassware was rigorously ﬂame-
dried and an inert (N2) atmosphere maintained throughout. All
solvents and chemicals were used as received unless stated. Chro-
matographic separations were performed using Merck Geduran
silica gel 60. Petroleum ether with a boiling range 40e60 C was
used.
4.2. (±)-(S)-2-(S)-Phenyl-(3,5-dibenzyloxyphenoxy)-methyl
oxirane (8)
A suspension of ()-9a (90 mg, 0.197 mmol) and Et3N (30 mL,
0.197 mmol) in EtOAc (1 mL) was cooled to20 C and treated with
J.C. Anderson et al. / Tetrahedron 70 (2014) 3485e34903488a solution of TMSCl (26 mL, 0.197 mmol) in EtOAc (0.4 mL) added
dropwise over 10 min. The resultant solution was stirred at 20 C
for 15 min and then treated with Et3N (30 mL, 0.197 mmol) followed
by a solution of MsCl (17 mL, 0.217 mmol) in EtOAc (0.4 mL) and
stirred for 20 min at 20 C. After this time HCl (2 M, 0.4 mL) was
added and the reaction mixture stirred at rt for 1 h. The reaction
mixture was washed with H2O (2 mL), NaHCO3(aq) (5 mL), brine
(5 mL), dried (Na2SO4), ﬁltered and concentrated in vacuo. The solid
was taken up in THF (1 mL) and treated with a mixture of NaOH
(35 mg, 0.450mmol) and Bu4NCl (3 mg, 0.010mmol) in H2O (1mL).
The resultant solution was stirred vigorously o/n. The reaction
mixture was extracted into EtOAc (25 mL), separated, dried
(MgSO4), ﬁltered and concentrated in vacuo. Puriﬁcation was ach-
ieved by ﬂash column chromatography (20% EtOAc/Pet. Ether) to
give 8 as a white solid (63 mg, 73%); mp 101e102 C; Rf (10% EtOAc/
Pet. Ether) 0.28; IR nmax 3025, 1594, 1451, 1375, 1144, 1057 cm1; 1H
NMR d 2.74 (1H, dd, J¼4.8, 2.6, C4H2), 2.84 (1H, appt, J¼4.4, C4H2),
3.38 (1H, ddd, J¼6.4, 4.1, 3.3, C3H), 4.82 (1H, d, J¼6.0, C2H), 4.94 (4H,
s, 2OCH2Ph), 6.19 (2H, d, J¼2.4, ArH), 6.21 (1H, t, J¼2.4, ArH),
7.31e7.39 (15H, m, ArH); 13C NMR d 45.1, 55.1, 70.2, 81.6, 95.4, 96.1,
126.6, 127.7, 128.1, 128.5, 128.7, 129.0, 136.8, 137.3, 159.6, 160.6; m/z
(EI) 438 (Mþ), 408 (MþH2CO), 347 (MþBn), 133, 91; HRMS m/z
(EI) C29H26O4 calcd 438.1831, found 438.1822.
4.3. General procedure for the synthesis of epoxy alcohols (6)
A suspension of CH2Cl2 (30 mL) over molecular sieves (4 g, 4 A,
powdered) was cooled to 20 C and treated with diethyl-L-tartrate
(0.08 equiv) followed by titanium isopropoxide (0.05 equiv) and t-
butyl hydroperoxide (2.1 equiv). The resultant solutionwas stirred at
20 C for 40 min and then treated with a solution of 3,5-
dibenzyloxycinnamyl alcohol14 (for 6b) or 3-benzyloxycinnamyl al-
cohol20 (for 6c) (2.47e4.16mmol) in CH2Cl2 (20mL), added dropwise
over 1 h. After stirring for 2 h the reaction was quenched NaOH
(0.21e0.33mL,10%aqueous solution saturatedwithNaCl) anddiethyl
ether added (6mL). The reactionmixturewas removed from the cold
bath, warmed to 10 C and stirred for 10 min after this time MgSO4
(0.21e0.33 g) and Celite (50 mg) were added, stirring was continued
for 15 min. The reaction mixture was then ﬁltered through Celite,
washed with diethyl ether (20 mL) and concentrated in vacuo. Puri-
ﬁcation was achieved by ﬂash column chromatography (30e50%
EtOAc/Pet. Ether). Enantiopurity was checked by conversion of the
alcohol to the Mosher ester. A solution of 6 (0.04 mmol) in CH2Cl2
(0.3 mL) was treated with a pre-mixed solution of Et3N (27 mL,
0.04mmol) andDMAP (5mg, 0.04mmol) in CH2Cl2 (0.3mL) followed
by (S)-a-methoxy-a-(triﬂuoromethyl)phenylacetyl chloride (9 mL,
0.044 mmol) and stirred for 5 min, TLC analysis indicated reaction
completion. The solution was concentrated and submitted for 1H
NMR analysis (CDCl3). The analogous reaction was performed using
racemic-3-(3-methoxy)-phenyl)-oxiran-2-yl) methanol and the dis-
tinctive double-doublets for the C4 peak compared.
4.3.1. (2S,3S)-3-(3,5-Bis(benzyloxy)-phenyl)-oxiran-2-yl methanol
(6b). Yield (804 mg, 70%) as a sticky white solid; Rf (40% EtOAc/Pet.
Ether) 0.25; [a]D22 25.9 (c 1.03, CHCl3). 1H NMR data agrees with
that published in the literature for the racemic compound.14 By
comparison of the diastereotopic peaks 6b was found to have an
enantiopurity of >20:1.
4.3.2. ((2S,3S)-3-(3-Benzyloxy)-phenyl)-oxiran-2-yl methanol
(6c). Yield (840 mg, 79%) as a white solid; mp 70e73 C; Rf (30%
EtOAc/Pet. Ether) 0.25; [a]D22 34.2 (c 1.03, CHCl3); IR nmax 3413,
3034, 2868, 1598, 1591, 1493, 1454, 1382, 1320, 1291, 1274, 1268,
1205, 1155, 1078, 1026 cm1; 1H NMR d 1.72 (1H, dd, J¼7.9, 5.2,
C4OH), 3.20 (1H, ddd, J¼4.0, 2.2, 1.9, C3H), 3.81 (1H, ddd, J¼12.4, 7.9,
3.7, C4H2), 3.92 (1H, d, J¼1.9, C2H), 4.05 (1H, ddd, J¼12.4, 5.2, 2.2,C4H2), 5.07 (2H, s, OCH2PH), 6.91e6.94 (3H, m, ArH), 7.26e7.29 (1H,
m, ArH), 7.32e7.36 (1H, m, ArH), 7.38e7.46 (4H, m, ArH); 13C NMR
d 55.5, 61.2, 62.4, 70.1, 111.9, 115.0, 118.5, 127.6, 128.2, 128.7, 129.8,
136.9, 138.5, 159.2; m/z (CI) 257 (22%, MþþH), 239 (41%, MþOH),
227 (61%), 213 (26%), 181 (26%), 161 (22%), 149 (41%, MþþHOH,
Bn), 137 (24%), 119 (39%), 91 (100%, Bn); HRMS C16H17O3
calcd 257.1172, found 257.1161. By comparison of the diastereotopic
peaks 6c was found to have an enantiopurity of >20:1.
4.4. General procedure for the synthesis of diols (9)
A solution of 3,5-dibenzoxyphenol21 (1.1 equiv) in anhydrous THF
(6 mL) was cooled to 0 C and treated with NaH (1.1 equiv). The re-
sultant suspension was stirred at rt for 90 min, after this time H2O
(9.5 mL) was added dropwise over 5 min followed by a solution of 6
(2.40e2.98 mmol, 1 equiv) in THF (6 mL). The resultant solutionwas
heated to reﬂux for 1e3duntil complete by TLC. The reactionmixture
was cooled to rt and concentrated in vacuo. Puriﬁcationwas achieved
by ﬂash column chromatography (20e70% EtOAc/Pet. Ether).
4.4.1. (2S,3R)-3-(3,5-Dibenzyloxyphenoxy)-3-phenylpropane-1,2-
diol (9a). Yield (629 mg, 57%) as a yellow solid; mp 135e137 C; Rf
(40% EtOAc/Pet. Ether) 0.25; [a]D228.7 (c 0.35, CHCl3); IR nmax 3532,
3371, 1595, 1451, 1154, 1053 cm1; 1H NMR d 1.99 (1H, dd, J¼7.4, 5.1,
C4OH), 2.21 (1H, d, J¼5.9, C3OH), 3.79e3.83 (2H, m, C4H2),
3.94e3.98 (1H, m, C3H), 4.93 (4H, s, 2OCH2Ph), 5.17 (1H, d, J¼6.0,
C2H), 6.13 (2H, d, J¼2.1, ArH), 6.20 (1H, t, J¼2.1, ArH), 7.30e7.41 (15H,
m, ArH); 13C NMR d 62.9, 70.2, 74.8, 81.1, 95.4, 96.0, 126.8, 127.7,
128.2, 128.5, 128.7, 129.0, 136.7, 137.6, 159.4, 160.6; m/z (CI) 457
(53%, MþþH), 439 (23%), 307 (100%); HRMS m/z (CI) C29H29O5
calcd 457.2015, found 457.2003.
4.4.2. (2S,3R)-3-(3,5-Dibenzyloxyphenoxy)-3-(3,5-dibenzyloxyphen
yl)-propane-1,2-diol (9b). Yield (919 mg, 61%) as a white solid; mp
66e68 C; Rf (40% EtOAc/Pet. Ether) 0.20; [a]D22 2.3 (c 1.10, CHCl3);
IR nmax 3403, 1597, 1454,1377, 1156, 1056 cm1; 1H NMR d 2.00e2.02
(1H, m, C4OH), 2.50 (1H, d, J¼5.9, C3OH), 3.73e3.81 (2H, m, C4H2),
3.89e3.94 (1H, m, C3H), 4.94 (4H, s, 2OCH2Ph), 5.01 (4H, s,
2OCH2Ph), 5.07 (1H, d, J¼5.9, C2H), 6.14 (1H, s, ArH), 6.14 (1H, s,
ArH), 6.23 (1H, br, ArH), 6.57 (1H, br, ArH), 6.61 (1H, s, ArH), 6.62 (1H,
s, ArH), 7.27e7.41 (20H,m, ArH); 13C NMR d 62.9, 70.2, 70.3, 74.7, 81.0,
95.4, 96.0, 101.9, 105.8, 127.7, 127.8, 128.21, 128.24, 128.69, 128.72,
136.6, 136.8, 140.1, 159.4, 160.4, 160.6; m/z (CI) 669 (62%, Mþ), 363
(28%, Mþ3Bn, OH2), 352 (82%), 207 (100%), 181 (25%), 91 (26%,
Bn); HRMS m/z (ES) C43H39O7 calcd 667.2696, found 667.2755.
4.4.3. (2S,3R)-3-(3,5-Dibenzyloxyphenoxy)-3-(3-benzyloxyphenyl)-
propane-1,2-diol (9c). Yield (1.30 g, 78%) as a white solid; mp
78e80 C; Rf (30% EtOAc/Pet. Ether) 0.25; [a]D2214.8 (c 1.14, CHCl3);
IR nmax 3406, 1594, 1450, 1378, 1260, 1154, 1060 cm1; 1H NMR
d 2.00e2.02 (1H, m, C4OH), 2.23 (1H, d, J¼5.4, C3OH), 3.75e3.81
(2H, m, C4H2), 3.91e3.94 (1H, m, C3H), 4.92 (4H, s, 2OCH2Ph), 5.03
(2H, s, OCH2Ph), 5.11 (1H, d, J¼5.9, C2H), 6.13 (1H, s, ArH), 6.13 (1H, s,
ArH), 6.91 (1H, dd, J¼8.1, 1.7, ArH), 6.94 (1H, d, J¼7.6, ArH), 6.98 (1H,
s, ArH), 7.26e7.42 (17H, m, ArH); 13C NMR d 62.9, 70.1, 70.2, 74.8,
80.9, 95.4, 96.0, 113.2, 114.8, 119.4, 127.71, 127.74, 128.18, 128.22,
128.71, 128.73, 130.1, 136.8 (2), 139.3, 159.3, 159.4, 160.6; m/z (CI)
563 (16%, MþþH), 545 (10%, MþOH), 338 (10%), 308 (21%), 307
(100%), 306 (12%), 239 (17%), 223 (13%); HRMS C36H35O6
calcd 563.2428, found 563.2427.
4.5. (S)-2-(R)-Phenyl-(3,5-dibenzyloxyphenoxy)-methyl oxir-
ane (10a)
A solution of 9a (450 mg, 0.980 mmol) in pyridine (2.5 mL) was
cooled to 0 C and treated with p-tosyl chloride (186 mg,
J.C. Anderson et al. / Tetrahedron 70 (2014) 3485e3490 34890.98 mmol). The resultant reaction mixture was stirred at rt for 2 d.
1 M HCl(aq) (20 mL) was added to the reaction mixture and the
solution was extracted wit EtOAc (315 mL). The organics were
washed with brine (220 mL), NaHCO3(aq) solution (30% wt,
220 mL), brine (215 mL), separated, dried (Na2SO4), ﬁltered and
concentrated in vacuo. The residue was taken up in MeOH (8 mL),
treated with K2CO3 (145 mg, 1.40 mmol) and stirred at rt o/n. After
this time H2O (20 mL) was added and the solution extracted Et2O
(320 mL), washed with brine (320 mL), dried (Na2SO4), ﬁltered
and concentrated in vacuo. Puriﬁcation was achieved by ﬂash col-
umn chromatography (10e50% EtOAc/Pet. Ether) to give 10a
(289 mg, 67%, (90% b.r.s.m.)) as a pale yellow solid; mp 90e93 C; Rf
(30% EtOAc/Pet. Ether) 0.64; [a]D22 2.8 (c 1.16, CHCl3); IR nmax 1595,
1450, 1378, 1260, 1153, 1060 cm1; 1H NMR d 2.79 (1H, dd, J¼5.2,
2.5, C4H2), 2.83 (1H, dd, J¼5.0, 4.0, C4H2), 3.32 (1H, dt, J¼4.0, 4.0,
C3H), 4.94 (4H, s, 2OCH2Ph), 5.08 (1H, d, J¼4.1, C2H), 6.16 (2H, d,
J¼2.1, ArH), 6.21 (1H, t, J¼2.1, ArH), 7.27e7.40 (15H, m, ArH); 13C
NMR d 45.1, 54.4, 70.2, 79.2, 95.4, 96.2, 126.8, 127.7, 128.1, 128.5,
128.7, 128.8, 136.8, 137.4, 159.5, 160.6; m/z (CI) 439 (100%, Mþ), 414
(71%), 240 (22%), 229 (42%), 87 (36%), 85 (75%); HRMS C29H27O4
calcd 439.1909, found 439.1893.
4.6. General procedure for the synthesis of epoxides (10)
A solution of 9 (1.33e1.42 mmol) in CH2Cl2 (30 mL) was treated
with Et3N (1.5 equiv), DMAP (0.025 equiv) and p-tosyl chloride
(1.2 equiv). The resultant reaction mixture was stirred at rt o/n. The
reaction mixture was washed with H2O (20 mL), separated, dried
(Na2SO4), ﬁltered and concentrated in vacuo. The residue was taken
up inMeOH (50mL), treatedwith K2CO3 (1.3 equiv) and stirred at rt
for 2 h. The solvent was removed in vacuo and the residue taken up
in EtOAc (40 mL), washed with H2O (20 mL), dried (MgSO4), ﬁltered
and concentrated in vacuo. Puriﬁcation was achieved by ﬂash col-
umn chromatography (10e50% EtOAc/Pet. Ether).
4.6.1. (S)-2-(R)-(3,5-Bis(benzyloxy)-phenyl)-(3,5-dibenzyloxypheno
xy)-methyl oxirane (10b). Yield (402 mg, 46%, (58% b.r.s.m.)) as
a white solid; mp 64e66 C; Rf (30% EtOAc/Pet. Ether) 0.46; [a]D20
16.1 (c 1.30, CHCl3); IR nmax 3063, 2864, 1594, 1444, 1379, 1354,
1290, 1158, 1080, 1056, 1028 cm1; 1H NMR d 2.80e2.82 (2H, m,
C4H2), 3.27e3.29 (1H, dt, J¼3.6, 3.2, C3H), 4.95 (4H, s, 2OCH2Ph),
4.99 (1H, d, J¼4.0, C2H), 5.02 (4H, s, 2OCH2Ph), 6.16 (2H, d, J¼1.9,
ArH), 6.23 (1H, t, J¼1.9, ArH), 6.58 (1H, t, J¼1.9, ArH), 6.67 (2H, d,
J¼1.9, ArH), 7.31e7.43 (20H, m, ArH); 13C NMR d 45.1, 54.5, 70.2,
70.3, 79.1, 95.5, 96.1, 101.9, 105.8, 127.2, 127.3, 127.8, 128.5, 128.9,
137.2, 143.0, 159.6, 160.3, 160.6; m/z (CI) 651 (100%, MþþH), 621
(15%), 414 (16%), 345 (21%), 307 (23%), 181 (17%); HRMS m/z (CI)
C43H39O6 calcd 651.2747, found 651.2739.
4.6.2. (S)-2-(R)-(3-Benzyloxyphenyl)-(3,5-dibenzyloxyphenoxy)-
methyl oxirane (10c). Yield (433 mg, 56%, (81% b.r.s.m.)) as a waxy
pale yellow solid; Rf (25% EtOAc/Pet. Ether) 0.60; [a]D2212.1 (c 0.73,
CHCl3); IR nmax 3032, 1598, 1454, 1379, 1262, 1156, 1056 cm1; 1H
NMR d 2.76e2.81 (2H, m, C4H2), 3.27e3.30 (1H, m, C3H), 4.93 (4H, s,
2OCH2Ph), 5.04 (3H, s, C2H, OCH2Ph), 6.15 (2H, d, J¼2.1, ArH), 6.21
(1H, t, J¼2.1, ArH), 6.92 (1H, dd, J¼8.1, 2.2, ArH), 6.98 (1H, d, J¼7.7,
ArH), 7.02 (1H, m, ArH), 7.27e7.48 (16H, m, ArH); 13C NMR d 45.1,
54.4, 70.1, 70.2, 79.0, 95.4, 96.1, 113.2, 114.8, 119.4, 127.7, 127.8, 128.1,
128.7, 129.9, 136.8, 136.9, 139.1, 159.2, 159.5, 160.6;m/z (EI) 544 (6%,
Mþ), 149 (30%), 123 (24%),111 (31%), 97 (52%), 83 (53%), 81 (61%), 69
(100%); HRMS C36H32O5 calcd 544.2244, found 544.2248.
4.7. General procedure for the synthesis of catechins (11)
A solution of 10 (0.691e0.958mmol) in HFIP (15mL) was heated
to reﬂux in a sealed tube for 12e15 d. After this time the solventwas distilled off and the residue puriﬁed by ﬂash column chro-
matography (5e25 % Et2O/Pet. Ether).
4.7.1. (2R,3S)-2-Phenyl-5,7-dibenzyloxy-chroman-3-ol (11a). Yield
(203mg, 46%, 56% b.r.s.m.) as awhite solid; mp 134e135 C; Rf (30%
EtOAc/Pet. Ether) 0.50; [a]D22 þ10.2 (c 0.29, CH2Cl2), (lit.5 (other
enantiomer) no mp reported, [a]D 8.7 (c 0.30, CH2Cl2)). 1H NMR
data agrees with those published in the literature for the other
enantiomer.8
4.7.2. (2R,3S)-2-(3,5-Bis-benzyloxy-phenyl)-5,7-dibenzyloxy-chro-
man-3-ol (11b). Yield (167 mg, 42%, 74% b.r.s.m.) as a white solid;
mp 100e102 C; Rf (25% EtOAc/Pet. Ether) 0.50; [a]D22 2.0 (c 1.04,
CHCl3); IR nmax 3567, 3064, 3032, 2916,1594,1498,1455,1375,1346,
1291, 1216,1150,1118,1053,1029 cm1; 1H NMR d 1.72 (1H, d, J¼3.6,
C3OH), 2.67 (1H, dd, J¼16.4, 8.8, C4H2), 3.10 (1H, dd, J¼16.4, 5.6,
C4H2), 4.03e4.90 (1H, m, C3H), 4.69 (1H, d, J¼8.0, C2H), 5.00 (2H, s,
OCH2Ph), 5.03 (4H, s, 2OCH2Ph), 5.04 (2H, s, OCH2Ph), 6.24 (1H, d,
J¼2.2, ArH), 6.27 (1H, d, J¼2.2, ArH), 6.61 (1H, t, J¼2.2, ArH), 6.69
(2H, d, J¼2.2, ArH), 7.32e7.39 (20H, m, ArH); 13C NMR d 27.6, 68.3,
70.0, 70.2, 70.3, 77.3, 81.8, 93.9, 94.4, 102.2, 102.4, 106.3, 127.3, 127.7,
127.7,128.0,128.1,128.2,128.6,128.7,128.7,136.7,136.9,137.0,140.4,
155.2, 157.9, 158.9, 160.4;m/z (EI) 650 (20%, MþH), 369 (32%), 355
(21%), 319 (17%), 242 (16%), 91 (100%, Bn); HRMS m/z (EI) C43H38O6
calcd 650.2663, found 650.2666.
4.7.3. (2R,3S)-2-(3-Benzyloxyphenyl)-5,7-dibenzyloxy-chroman-3-ol
(11c). Yield (150 mg, 33%, 71% b.r.s.m.) as a white solid; mp
86e88 C; Rf (25% EtOAc/Pet. Ether) 0.47; [a]D224.0 (c 0.98, CHCl3);
IR nmax 3417, 3032, 2907, 1617, 1592, 1496, 1441, 1377, 1289, 1218,
1150, 1118, 1049, 1029 cm1; 1H NMR d 1.72 (1H, s, C3OH), 2.69 (1H,
dd, J¼16.4, 8.6, C4H2), 3.10 (1H, dd, J¼16.4, 5.6, C4H2), 4.09e4.10 (1H,
m, C3H), 4.75 (1H, d, J¼7.9, C2H), 5.00 (2H, s, OCH2Ph), 5.03 (2H, s,
OCH2Ph), 5.07 (2H, s, OCH2Ph), 6.24 (1H, d, J¼2.2, ArH), 6.28 (1H, d,
J¼2.2, ArH), 6.97 (1H, dd, J¼8.3, 2.3, ArH), 7.03 (1H, d, J¼7.7, ArH),
7.07 (1H, m, ArH), 7.31e7.40 (16H, m, ArH); 13C NMR d 27.6, 68.3,
70.0, 70.1, 70.2, 77.3, 81.8, 93.9, 94.4, 102.2, 113.6, 115.2, 119.8, 127.3,
127.7, 127.7, 128.0, 128.1, 128.2, 128.7, 128.7, 128.7, 130.1, 136.8, 137.0,
137.0, 139.7, 155.3, 157.9, 158.9, 159.2; m/z (CI) 545 (100%, MþH),
545 (18%, Mþ), 527 (16%), 319 (16%); HRMS m/z (CI) C36H32O5
calcd 545.2323, found 545.2328.4.8. General procedure for the synthesis of epicatechins (7)
Step 1: A solution of 11 (0.150e0.460 mmol) in wet CH2Cl2
(3e15 mL) was cooled to 0 C and treated with DesseMartin
periodinane (1.2 equiv). The resultant solution was stirred at rt o/n.
The reaction mixture was washed with 1 M NaOH(aq), back
extracted with CH2Cl2, organics combined and washed with brine,
dried (MgSO4), ﬁltered and concentrated in vacuo. Puriﬁcation was
achieved by ﬂash column chromatography (10% EtOAc/Pet. Ether).
Step 2: A solution of ketone (0.142e0.330 mmol) in anhydrous
THF (5 mL) was cooled to 78 C and treated with L-Selectride
(1.4 equiv, 1 M in THF). The resultant solution was stirred at 78 C
for 2 h. The reactionmixturewas taken up in EtOAc (10mL) washed
with H2O (5 mL), back extracted with EtOAc (10 mL), organics
combined and dried (Na2SO4), ﬁltered and concentrated in vacuo.
Puriﬁcation was achieved by ﬂash column chromatography (15%
EtOAc/Pet. Ether).
4.8.1. (2R,3R)-2-Phenyl-5,7-dibenzyloxy-chroman-3-ol7 (7a)
4.8.1.1. Step 1: (2R)-2-(3,5-bis-benzyloxy-phenyl)-5,7-dibenzylo
xy-chroman-3-on. Yield (125 mg, 63%) as a white solid; mp
109e111 C; Rf (30% EtOAc/Pet. Ether) 0.75; [a]D22 þ16.5 (c 0.74,
CHCl3); IR nmax 2919, 2872, 1731, 1594, 1451, 1378, 1152, 1027 cm1;
J.C. Anderson et al. / Tetrahedron 70 (2014) 3485e349034901H NMR d 3.51 (1H, d, J¼22.4, C4H2), 3.67 (1H, d, J¼22.4, C4H2), 5.02
(2H, s, OCH2Ph), 5.05 (2H, s, OCH2Ph), 5.36 (1H, s, C2H), 6.36 (1H, d,
J¼2.2, ArH), 6.41 (1H, d, J¼2.1, ArH), 7.33e7.45 (15H, m, ArH); 13C
NMR d 33.9, 70.2, 70.4, 83.6, 95.2, 95.9, 102.0, 126.8, 127.3, 127.7,
128.2, 128.3, 128.7, 128.7, 128.8, 128.8, 135.2, 136.6, 136.7, 154.7,
157.2, 159.6, 205.2; m/z (CI) 437 (100%, MþþH), 414 (25%), 219
(20%), 181 (22%), 91 (85%, Bn); HRMS m/z (CI) C29H25O4
calcd 437.1753, found 437.1749.
4.8.1.2. Step 2: (2R,3R)-2-phenyl-5,7-dibenzyloxy-chroman-3-
ol.7 Yield (91 mg, 72%) as a waxy solid; Rf (25% Et2O/Pet. Ether)
0.21; [a]D22 11.0 (c 0.45, CH2Cl3), (lit.7 [a]D20 10.5 (c 0.40, CH2Cl2)).
1H NMR data agrees with those published in the literature.7
4.8.2. (2R,3R)-2-(3,5-Bis-benzyloxy-phenyl)-5,7-dibenzyloxy-chro-
man-3-ol7 (7b)
4.8.2.1. Step 1: (2R)-2-(3,5-bis-benzyloxy-phenyl)-5,7-
dibenzyloxy-chroman-3-one. Yield (94 mg, 57%, (73% b.r.s.m.)) as
a white solid; mp 112e114 C; Rf (10% EtOAc/Pet. Ether) 0.34; [a]D22
þ24.6 (c 1.06, CHCl3); IR nmax 3032, 2919, 2872, 1732, 1619, 1595,
1498,1453,1441,1376,1348,1293,1217,1179,1152,1099,1081,1052,
1029 cm1; 1H NMR d 3.49 (1H, d, J¼21.4, C4H2), 3.63 (1H, d, J¼21.4,
C4H2), 4.99 (4H, s, 2OCH2Ph), 5.02 (2H, s, OCH2Ph), 5.04 (2H, s,
OCH2Ph), 5.29 (1H, s, C2H), 6.35 (1H, d, J¼2.0, ArH), 6.40 (1H, d,
J¼1.9, ArH), 6.58 (1H, t, J¼1.9, ArH), 6.64 (2H, d, J¼2.0, ArH),
7.32e7.40 (20H, m, ArH); 13C NMR d 33.8, 70.2, 70.2, 70.4, 83.3, 95.2,
95.8, 101.9, 102.3, 105.8, 127.4, 127.7, 127.8, 128.2, 128.3, 128.7, 128.8,
136.6, 136.7, 137.4, 154.5, 157.2, 159.6, 160.2, 204.8;m/z (CI) 649 (4%,
MþþH), 614 (28%), 414 (100%), 219 (74%), 91 (86%, Bn); HRMS m/z
(CI) C43H37O6 calcd 649.2590, found 649.2589.
4.8.2.2. Step 2: (2R,3R)-2-(3,5-bis-benzyloxy-phenyl)-5,7-
dibenzyloxy-chroman-3-ol.7 Yield (63 mg, 68%) as a white solid;
mp 121e123 C; Rf (20% EtOAc/Pet. Ether) 0.64; [a]D22 17.8 (c 0.8,
CH2Cl2), (lit.7 [a]D 17.2 (c 0.8, CH2Cl2, no mp reported)). 1H NMR
data agrees with literature data.7
4.8.3. (2R,3R)-2-(3-Benzyloxy-phenyl)-5,7-dibenzyloxy-chroman-3-
ol7 (7c)
4.8.3.1. Step 1: (2R)-2-(3-benzyloxyphenyl)-5,7-dibenzyloxy-
chroman-3-one. Yield (36 mg, 44%, 68% b.r.s.m.) as a white solid;
mp 100e102 C; Rf (10% EtOAc/Pet. Ether) 0.36; [a]D22 þ17.4 (c 1.25,
CHCl3); IR nmax 2921, 1733, 1620, 1595, 1498, 1454, 1441, 1377, 1293,
1217, 1179, 1152, 1099, 1081, 1052, 1029 cm1; 1H NMR d 3.49 (1H, d,
J¼21.4, C4H2), 3.65 (1H, d, J¼21.4, C4H2), 5.01 (2H, s, OCH2Ph), 5.02
(2H, s, OCH2Ph), 5.04 (2H, s, OCH2Ph), 5.33 (1H, s, C2H), 6.35 (1H, d,
J¼2.2, ArH), 6.40 (1H, d, J¼2.1, ArH), 6.94 (1H, dd, J¼8.2, 2.3, ArH),
6.94 (1H, d, J¼7.8, ArH), 7.01 (1H, m, ArH), 7.26e7.48 (16H, m, ArH);
13C NMR d 33.8, 70.1, 70.2, 70.3, 83.3, 95.2, 95.9, 113.2, 115.1, 119.3,
127.3, 127.7, 128.2, 128.2, 128.3, 128.7, 128.8, 129.9, 136.6, 136.7,
136.8, 154.6, 157.2, 159.1, 159.6, 205.0; m/z (CI) 543 (26%, MþþH),
414 (100%), 219 (72%), 111 (16%); HRMS C36H31O5 calcd 543.2172,
found 543.2175.
4.8.3.2. Step 2: (2R,3R)-2-(3-benzyloxy-phenyl)-5,7-dibenzyloxy-
chroman-3-ol.7 Yield (66 mg, 74%) as a white solid; mp 112e114 C;
Rf (20% EtOAc/Pet. Ether) 0.58; [a]D2228.1 (c 1.06, CH2Cl2), (lit.7 [a]D
25.7 (c 3.4, CH2Cl2, no mp reported)). 1H NMR data agrees with
literature data.7
4.9. Synthesis of (2S,3R)-trans-ﬂavan-3-ol (12)8
Synthesised according to the procedure of Krohn et al. using
(1R,2R)-3-(2-hydroxyphenyl)-1-phenylpropane-1,2-diol in place of(1S,2S)-3-(2-hydroxyphenyl)-1-phenylpropane-1,2-diol to give the
opposite enantiomer.18 Yield (88 mg, 46%, (66% b.r.s.m)) as a white
solid; mp 70e72 C; [a]D20 þ8.51 (c 1.32, CH2Cl2), (lit. mp and [a]D
not reported). 1H NMR agrees with literature data for racemic
material.224.10. Synthesis of hydroxyl deleted A and B ring catechin
gallates (5)
4.10.1. (þ)-(2R,3S)-trans-Phenylﬂavan-3-yl-3,4,5-tris(benzyloxy)
benzoate. Synthesised according to the procedure of Anderson
et al. using (2S,3R)-trans-ﬂavan-3-ol in place of (2R,3S)-trans-ﬂa-
van-3-ol to give the opposite enantiomer.8 Yield (165 mg, 62%) as
a white solid; mp 121e123 C; [a]D20 þ60.5 (c 0.50, CH2Cl2), (lit.8 mp
126e128 C, [a]D20 65.0 (c 0.50, CH2Cl2) opposite enantiomer). 1H
NMR agrees with literature data for opposite enantiomer.8
4.10.2. (þ)-(2R,3S)-trans-Phenylﬂavan-3-yl-O-gallate (5). A solu-
tion of (þ)-(2R,3S)-trans-phenylﬂavan-3-yl-3,4,5-tris(benzyloxy)
benzoate (55 mg, 0.084 mmol) in EtOAc (10 mL) and MeOH (10 mL)
was treated with Pd(OH)2/C (42 mg) and back ﬁlled with H2 (three
times). Stirred at rt for 2.5 h, ﬁltered through Celite, washed with
EtOAc (10 mL) and concentrated to give 5 (27 mg, 85%) as an off
white solid; mp 210e212 C; [a]D20 þ95.1 (c 0.30, acetone), (lit.8 mp
not reported, [a]D20 97.0 (c 0.3, acetone) opposite enantiomer). 1H
NMR agrees with literature data for opposite enantiomer.8Acknowledgements
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